Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
T cell–intrinsic VISTA expression promotes resistance to CTLA-4 blockade by restricting CD8+ T cell responses
Cassandra Gilmour, Elizabeth DeLaney, Prerana B. Parthasarathy, Dia Roy, Hieu M. Ta, Amin Zakeri, Paolo Elguera Grandez, Sachin Patnaik, Keman Zhang, Ivan Juric, Rahul Rangan, Zahraa Al-Hilli, Anthony Tufaro, Booki Min, Samuel E. Weinberg, Timothy A. Chan, Natalie L. Silver, Stefanie Avril, Tyler Alban, Li Lily Wang
Cassandra Gilmour, Elizabeth DeLaney, Prerana B. Parthasarathy, Dia Roy, Hieu M. Ta, Amin Zakeri, Paolo Elguera Grandez, Sachin Patnaik, Keman Zhang, Ivan Juric, Rahul Rangan, Zahraa Al-Hilli, Anthony Tufaro, Booki Min, Samuel E. Weinberg, Timothy A. Chan, Natalie L. Silver, Stefanie Avril, Tyler Alban, Li Lily Wang
View: Text | PDF
Research Article Immunology Oncology

T cell–intrinsic VISTA expression promotes resistance to CTLA-4 blockade by restricting CD8+ T cell responses

  • Text
  • PDF
Abstract

V-domain immunoglobulin suppressor of T cell activation (VISTA) is an immune checkpoint protein that impairs antitumor T cell responses. While broadly expressed on myeloid cells and T cells, the specific contribution of T cell–intrinsic VISTA to antitumor immunity remains undefined. This study investigated the phenotypic and functional consequences of T cell–specific VISTA deletion in tumor-specific CD8+ T cells. Single-cell transcriptomic analysis, TCR repertoire profiling, and flow cytometry revealed that loss of T cell–intrinsic VISTA enhanced early priming and short-term expansion of CD8+ T cells, yet this initial advantage failed to confer durable tumor control. Persistent dysfunction in VISTA-deficient T cells was in part driven by trans-VISTA on myeloid cells, while CTLA-4 upregulation further constrained T cell responses. T cell–intrinsic VISTA deficiency cooperated with CTLA-4 blockade to improve T cell survival and broaden TCR repertoire diversity, resulting in more robust tumor regression than CTLA-4 inhibition alone. A transcriptional signature enriched in VISTA-deficient cytotoxic T cells correlated with favorable outcomes in cancer patients treated with existing immune checkpoint inhibitors. These findings collectively define T cell–intrinsic mechanisms by which VISTA enforces T cell dysfunction and underscore its potential as both a therapeutic target and a biomarker of resistance to current immunotherapies.

Authors

Cassandra Gilmour, Elizabeth DeLaney, Prerana B. Parthasarathy, Dia Roy, Hieu M. Ta, Amin Zakeri, Paolo Elguera Grandez, Sachin Patnaik, Keman Zhang, Ivan Juric, Rahul Rangan, Zahraa Al-Hilli, Anthony Tufaro, Booki Min, Samuel E. Weinberg, Timothy A. Chan, Natalie L. Silver, Stefanie Avril, Tyler Alban, Li Lily Wang

×

Figure 3

Myeloid-derived VISTA exerted a stronger suppressive effect on antitumor T cell responses than T cell–intrinsic VISTA.

Options: View larger image (or click on image) Download as PowerPoint
Myeloid-derived VISTA exerted a stronger suppressive effect on antitumor...
(A and B) T cell–specific VISTA-KO mice (Vsirfl/fl CD4Cre) (A), myeloid-specific VISTA-KO mice (Vsirfl/fl Cx3cr1Cre) (B), and WT controls (Vsirfl/fl) were inoculated with B16bl6 melanoma cells and treated with a TRP2 peptide vaccine on days 3 and 10. Tumor growths were monitored by a caliper. (C–G) WT and VISTA conditional KO mice as indicated were inoculated with B16bl6 melanoma cells and treated with 1 reduced dose of vaccine. Phenotypes of CD8+ TILs were examined by flow cytometry on days 14–16 after vaccine treatment. Normalized numbers of CD8+ TILs are shown in C. TCF1 expression levels, measured as MFI, and frequencies of TCF1+TIM3– stem-like cells are shown in D. Frequencies of TCF1+CD62L+PD-1– quiescent T cells are shown in E. Frequencies of TCF1–Tim3+ T cells and TIM3 expression levels are shown in F. Granzyme B expression is shown in G. (H) Mice were inoculated with B16bl6 melanoma and treated with peptide vaccine on days 3 and 10 or treated with anti-VISTA antibodies (200 mg per mouse) every 2–3 days. Mice survival up to 60 days after tumor inoculation is shown. Data are presented as mean ± SEM. For A, N = 10 (Vsirfl/fl) and 9 (Vsirfl/fl CD4Cre). For B, N = 10 (Vsirfl/fl) and 11 (Vsirfl/fl Cx3cr1Cre). For C–E, N = 7 (Vsirfl/fl), 11 (Vsirfl/fl CD4Cre), and 7 (Vsirfl/fl Cx3cr1Cre). For F, N = 12 (Vsirfl/fl), 16 (Vsirfl/fl CD4Cre), and 10 (Vsirfl/fl Cx3cr1Cre). For G, N = 7 (Vsirfl/fl), 6 (Vsirfl/fl CD4Cre), and 7 (Vsirfl/fl Cx3cr1Cre). For H, N = 7 (Vsirfl/fl), 10 (Vsirfl/fl+mAb), 9 (Vsirfl/fl CD4Cre), and 10 (Vsirfl/flCD4Cre+mAb). **P < 0.01, ***P < 0.001, ****P < 0.0001. Significance was determined using 2-way ANOVA with a Šidák’s multiple-comparison test (A and B), 1-way ANOVA (C and E–G), or log-rank Mantel-Cox test (H). All experiments were repeated 2–3 times.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts